Infection‐Associated Immune Reconstitution Inflammatory Syndrome in Hematopoietic Cell Transplantation
Transplant Infectious Disease · 2025-03 · 27 (2)
DOI: 10.1111/tid.70000 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, online erschienen am 18.02.2025. Verfasst von Mansi Chaturvedi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Critical Care Medicine and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Immune Reconstitution Inflammatory Syndrome, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: NIH HHS, National Institute of Allergy and Infectious Disease, NCI NIH HHS.
Abstract (Originalsprache)
Immune reconstitution inflammatory syndrome (IRIS) is a well‐recognized complication in people with HIV (PWH) starting antiretroviral therapy (ART), but data on IRIS in hematopoietic cell transplantation (HCT) recipients are limited. To address this gap, we conducted a narrative review of the literature on IRIS in HCT recipients, including 21 studies encompassing 53 patients. The majority of reported patients had inborn errors of immunity (IEI) and developed IRIS associated with Bacillus Calmette–Guérin (BCG)‐infection from prior vaccination (“BCG‐IRIS”). The remainder had IRIS linked to other infections, most commonly Aspergillus and Non‐tuberculous mycobacteria (“non–BCG‐IRIS”). The median time between transplant and IRIS was 3 months; however, some patients developed IRIS multiple years posttransplant. BCG‐IRIS was predominantly unmasking, while non–BCG‐IRIS was mostly associated with a new infection acquired after HCT alongside immune recovery and/or changes in immunosuppression (“post‐HCT infection IRIS”). Inflammatory biomarkers and tissue pathology were helpful in distinguishing IRIS from uncontrolled infection. Initiation or continuation of appropriate antimicrobial therapy in the peri‐transplant period was foremost in the prevention and treatment of IRIS. Use of steroidal and nonsteroidal immunosuppression was common, while surgery was used as an adjunctive measure to infection control. Recrudescence of IRIS symptoms was common with discontinuation or decrease in immunosuppression. About one‐third of the patients were reported to have graft‐versus‐host disease, and the rate of graft failure was 8%. The mortality rate was 15%, with most deaths attributed to superimposed infections. Through this review, we aim to highlight that IRIS is an under‐recognized entity in HCT recipients and future research is needed to explore its pathogenesis, risk factors, and management in this complex patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Critical Care Medicine and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Division of Pulmonary, Critical Care Medicine and Sleep Medicine, University of Maryland, Baltimore, Maryland, USA.
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- National Institutes of Health Library, Office of Research Services, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
- Center for Infectious Disease Imaging, NIH Clinical Center, NIH, Bethesda, Maryland, USA.
ORCID-Profile: Mansi Chaturvedi, Jennifer Cuellar-Rodriguez, Maura Manion
Förderung
- NIH HHS
- National Institute of Allergy and Infectious Disease
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chaturvedi, M., Epling, B. P., Pei, L., Sullivan, B., Kuehn, H. S., Hammoud, D. A., Rosenzweig, S., Pai, S. Y., Sereti, I., Freeman, A. F., Cuellar-Rodriguez, J., Gonzalez, C. E., & Manion, M. (2025). Infection‐Associated Immune Reconstitution Inflammatory Syndrome in Hematopoietic Cell Transplantation. Transplant Infectious Disease, 27(2). https://doi.org/10.1111/tid.70000
Vancouver
Chaturvedi M, Epling BP, Pei L, Sullivan B, Kuehn HS, Hammoud DA, et al. Infection‐Associated Immune Reconstitution Inflammatory Syndrome in Hematopoietic Cell Transplantation. Transplant Infectious Disease. 2025;27(2). doi:10.1111/tid.70000
BibTeX
@article{Chaturvedi2025,
author = {Chaturvedi, Mansi and Epling, Brian P and Pei, Luxin and Sullivan, Brigit and Kuehn, Hye Sun and Hammoud, Dima A and Rosenzweig, Sergio and Pai, Sung-Yun and Sereti, Irini and Freeman, Alexandra F and Cuellar-Rodriguez, Jennifer and Gonzalez, Corina E and Manion, Maura},
title = {Infection‐Associated Immune Reconstitution Inflammatory Syndrome in Hematopoietic Cell Transplantation},
journal = {Transplant Infectious Disease},
year = {2025},
volume = {27},
number = {2},
doi = {10.1111/tid.70000}
}
EUVIMED